Alon Ben-Noon, Chief Executive Officer at NeuroSense Therapeutics Ltd. (NRSN), bought 250,000 shares at $0.80 ($200K) on 2026-06-16, disclosed to the SEC on 2026-06-17.
CEO Alon Ben-Noon purchased 250,000 shares for $200,000 at $0.80 per share on June 16, 2026, marking the largest purchase of his career. This significant insider buying, combined with the CEO's direct ownership interest, suggests confidence in the company's near-term prospects.
Insufficient data — needs manual review
Insufficient data — needs manual review
The stock carries elevated volatility risk, evidenced by a beta of 1.54, and faces potential pressure from short sellers holding 1.32% of the float.
Something here stands out, but not much.